Health1 min read

Pancreatic cancer halted by virus injection in three patients

By · Published by Everything Blog

In short

The early clinical trial administered the experimental adenovirus at one-tenth of the targeted dose, successfully halting tumor growth in all three participants. The modified virus targets cells rich in the cyclooxygenase-2 enzyme, causing them to burst, propagate the viral agent, and potentially alert the immune system. Researchers plan to advance the study by dosing 15 additional participants to identify the optimal therapeutic level. They also aim to explore combination therapies using checkpoint inhibitors to counter the cancer's evasive immune defenses.

Key points

  • Researchers intend to administer higher treatment doses to an additional 15 patients to i…: Researchers intend to administer higher treatment doses to an additional 15 patients to identify the optimal therapy level.
  • The therapeutic approach may eventually be paired with checkpoint inhibitor immunotherapi…: The therapeutic approach may eventually be paired with checkpoint inhibitor immunotherapies to improve overall immune response against the tumors.
  • Independent medical experts caution that the early findings lack a control group and must…: Independent medical experts caution that the early findings lack a control group and must demonstrate efficacy in late-stage Phase III trials.

Sources checked by our analysis pipeline: 1

A virus has stopped pancreatic cancer in its tracks in three people in a clinical trial in the US. Further evaluation is needed in larger trials, but the early results are encouraging, especially since only small doses of the virus were administered for initial safety testing.

“We only injected one-tenth of the dose we are eventually aiming at, so the efficacy is better than I expected, especially as this is pancreatic cancer,” says Masato Yamamoto at the University of Minnesota, who led the development of the viral treatment.

Pancreatic cancer is notorious for being the deadliest type of the condition. One reason is that symptoms tend to appear late, when the cancer has already spread and cannot be surgically removed. Once diagnosed, people usually live only around three to six months.

Advertisement

Another reason is that pancreatic tumours have tough, fibrous exteriors that block chemotherapy drugs from getting in. “They’re hard as hockey pucks,” says Yamamoto. Immunotherapies that boost immune activity against cancer are also ineffective, because pancreatic tumours can hide from the immune system.

The first patient in the…

Health